Show simple item record

dc.contributor.authorVagnildhaug, Ola Magne
dc.contributor.authorBrunelli, Cinzia
dc.contributor.authorHjermstad, Marianne Jensen
dc.contributor.authorStrasser, Florian
dc.contributor.authorBaracos, Vickie
dc.contributor.authorWilcock, Andrew
dc.contributor.authorNabal, María
dc.contributor.authorKaasa, Stein
dc.contributor.authorLaird, Barry J
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.date.accessioned2019-12-06T09:18:38Z
dc.date.available2019-12-06T09:18:38Z
dc.date.created2019-09-16T12:48:32Z
dc.date.issued2019
dc.identifier.citationBMC Palliative Care. 2019, 18:46 1-10.nb_NO
dc.identifier.issn1472-684X
dc.identifier.urihttp://hdl.handle.net/11250/2632115
dc.description.abstractBackground Early intervention against cachexia necessitates a predictive model. The aims of this study were to identify predictors of cachexia development and to create and evaluate accuracy of a predictive model based on these predictors. Methods A secondary analysis of a prospective, observational, multicentre study was conducted. Patients, who attended a palliative care programme, had incurable cancer and did not have cachexia at baseline, were amenable to the analysis. Cachexia was defined as weight loss (WL) > 5% (6 months) or WL > 2% and body mass index< 20 kg/m2. Clinical and demographic markers were evaluated as possible predictors with Cox analysis. A classification and regression tree analysis was used to create a model based on optimal combinations and cut-offs of significant predictors for cachexia development, and accuracy was evaluated with a calibration plot, Harrell’s c-statistic and receiver operating characteristic curve analysis. Results Six-hundred-twenty-eight patients were included in the analysis. Median age was 65 years (IQR 17), 359(57%) were female and median Karnofsky performance status was 70(IQR 10). Median follow-up was 109 days (IQR 108), and 159 (25%) patients developed cachexia. Initial WL, cancer type, appetite and chronic obstructive pulmonary disease were significant predictors (p ≤ 0.04). A five-level model was created with each level carrying an increasing risk of cachexia development. For Risk-level 1-patients (WL < 3%, breast or hematologic cancer and no or little appetite loss), median time to cachexia development was not reached, while Risk-level 5-patients (WL 3–5%) had a median time to cachexia development of 51 days. Accuracy of cachexia predictions at 3 months was 76%. Conclusion Important predictors of cachexia have been identified and used to construct a predictive model of cancer cachexia.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleA prospective study examining cachexia predictors in patients with incurable cancernb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-10nb_NO
dc.source.volume18:46nb_NO
dc.source.journalBMC Palliative Carenb_NO
dc.identifier.doi10.1186/s12904-019-0429-2
dc.identifier.cristin1725082
dc.description.localcodeOpen Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO
cristin.unitcode1920,12,0,0
cristin.unitcode194,65,15,0
cristin.unitnameKreftklinikken
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal